FMR LLC increased its stake in shares of Horizon Therapeutics PLC (NASDAQ:HZNP) by 165.1% in the first quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund owned 5,205,217 shares of the biopharmaceutical company’s stock after purchasing an additional 3,242,071 shares during the quarter. FMR LLC owned approximately 2.82% of Horizon Therapeutics worth $137,575,000 as of its most recent SEC filing.
Other hedge funds and other institutional investors also recently modified their holdings of the company. Norges Bank acquired a new position in Horizon Therapeutics during the 4th quarter valued at about $46,493,000. D. E. Shaw & Co. Inc. increased its holdings in shares of Horizon Therapeutics by 63.8% in the fourth quarter. D. E. Shaw & Co. Inc. now owns 3,369,508 shares of the biopharmaceutical company’s stock valued at $65,840,000 after purchasing an additional 1,312,142 shares during the period. Victory Capital Management Inc. acquired a new position in shares of Horizon Therapeutics in the first quarter valued at about $27,663,000. Two Sigma Investments LP grew its holdings in Horizon Therapeutics by 84.1% during the fourth quarter. Two Sigma Investments LP now owns 1,763,588 shares of the biopharmaceutical company’s stock worth $34,461,000 after acquiring an additional 805,770 shares during the period. Finally, Teacher Retirement System of Texas acquired a new stake in Horizon Therapeutics during the first quarter worth about $15,473,000. Hedge funds and other institutional investors own 89.09% of the company’s stock.
Several analysts recently commented on HZNP shares. Citigroup raised their target price on Martin Marietta Materials from $239.00 to $255.00 and gave the stock a “buy” rating in a report on Wednesday, May 1st. Cantor Fitzgerald increased their price target on Horizon Therapeutics from $26.00 to $32.00 and gave the stock a “buy” rating in a research report on Tuesday, April 2nd. Mizuho set a $27.00 price target on Horizon Therapeutics and gave the stock a “hold” rating in a research report on Wednesday, May 8th. BMO Capital Markets set a $13.00 price target on Vale and gave the stock a “hold” rating in a research report on Thursday, April 4th. Finally, BidaskClub upgraded WhiteHorse Finance from a “sell” rating to a “hold” rating in a research report on Thursday. Four investment analysts have rated the stock with a hold rating and ten have issued a buy rating to the company’s stock. Horizon Therapeutics presently has a consensus rating of “Buy” and an average price target of $31.91.
Horizon Therapeutics (NASDAQ:HZNP) last announced its quarterly earnings results on Wednesday, May 8th. The biopharmaceutical company reported $0.30 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.10 by $0.20. The company had revenue of $280.00 million during the quarter, compared to the consensus estimate of $238.35 million. Horizon Therapeutics had a return on equity of 33.57% and a net margin of 3.79%. Horizon Therapeutics’s revenue for the quarter was up 25.0% on a year-over-year basis. During the same period in the previous year, the business earned $0.03 EPS. As a group, research analysts anticipate that Horizon Therapeutics PLC will post 1.62 earnings per share for the current fiscal year.
In other Horizon Therapeutics news, insider Jeff Kent sold 3,620 shares of the stock in a transaction on Wednesday, June 5th. The stock was sold at an average price of $24.64, for a total transaction of $89,196.80. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, EVP Vikram Karnani sold 13,111 shares of the stock in a transaction on Monday, July 1st. The stock was sold at an average price of $25.02, for a total value of $328,037.22. The disclosure for this sale can be found here. 4.10% of the stock is owned by insiders.
Horizon Therapeutics Company Profile
Horizon Therapeutics Public Limited Company, a biopharmaceutical company, focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. Its orphan and rheumatology marketed medicines include KRYSTEXXA, a medicine for the treatment of uncontrolled gout; RAVICTI for use as a nitrogen-binding agent for chronic management of adult and pediatric patients; PROCYSBI for nephropathic cystinosis, a rare and life-threatening metabolic disorder; ACTIMMUNE for chronic granulomatous disease; RAYOS for the treatment of multiple conditions, rheumatoid arthritis; BUPHENYL tablets for oral administration and BUPHENYL powder for oral, nasogastric, or gastrostomy tube administration; and QUINSAIR, a formulation of the antibiotic drug levofloxacin for the management of chronic pulmonary infections due to Pseudomonas aeruginosa in adult patients with cystic fibrosis.
Featured Article: New Google Finance Tool and Screening Stocks
Receive News & Ratings for Horizon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.